© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
May 09, 2022
According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.
May 04, 2022
Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.
May 03, 2022
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
April 29, 2022
Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.
April 09, 2022
According to the company, the trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations.
March 22, 2022
Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.
February 14, 2022
During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
February 14, 2022
Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.
February 12, 2022
Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
Virtual reality gives ophthalmology students chance to view pupil abnormalities
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients